Home›Research›Compare›CJC-1295 (without DAC) vs IGF-1
Peptide ComparisonCJC-1295 (without DAC) vs IGF-1
Both are GH / IGF Axis peptides.
CJC-1295 (without DAC)
CJC 1295
Half-life: ~30 minutes
454 providers listed
IGF-1
Insulin-like Growth Factor 1
21 providers listed
IGF-1 is FDA-approved, while CJC-1295 (without DAC) is nomination withdrawn — the clearest structural difference between them.
CJC-1295 (without DAC)
Half-life
~30 minutes
IGF-1
Half-life
—
| Your goal | Better option |
|---|---|
| Stronger clinical evidence | CJC-1295 (without DAC) |
| Further along in FDA review | IGF-1 |
| Lower typical price per mg | CJC-1295 (without DAC) |
| More provider options (454 vs 21) | CJC-1295 (without DAC) |
Research summary only — not medical advice. Consult a qualified provider before making any decisions.
CJC-1295 (without DAC)
IGF-1
CJC-1295 (without DAC)
Endocrine and metabolic effects of long-term administration of [Nle27]growth hormone-releasing hormone-(1-29)…
Effects of [norleucine27]growth hormone-releasing hormone (GHRH) (1-29)-NH2 administration on the immune syst…
Injectable Peptides in Sports Medicine: A Structured Narrative Review of Evidence, Safety, and Antidoping Imp…
About CJC-1295 (without DAC)
CJC-1295 without DAC (Mod GRF 1-29) is a short-acting GHRH analog that binds and activates pituitary GHRH receptors to stimulate brief, pulsatile growth hormone release. Lacking the Drug Affinity Complex, it is not albumin-bound and clears within roughly half an hour, producing discrete GH pulses rather than the sustained elevation of the DAC form.
About IGF-1
Binds IGF-1R with high affinity, activating PI3K/Akt and MAPK pathways promoting protein synthesis, satellite cell activation, and glucose uptake. Much shorter half-life (~15 min) than the LR3 analog (~20-30 hr) due to binding protein interactions.
Information below reflects published research data only — not medical advice. Consult a qualified provider before use.
CJC-1295 (without DAC)
Class-based (investigational)
Research protocols routinely measure IGF-1 to track GH axis activity before and during use. Fasting glucose and insulin are monitored because GH elevation can reduce insulin sensitivity over time.
global — WADA
This compound falls under WADA Prohibited List category S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics), prohibited at all times for competing athletes.
sourceIGF-1
Under clinical review
Being verified by our medical team before we display contraindications for this peptide.
Under clinical review
Being verified by our medical team before we display monitoring guidance for this peptide.
CJC-1295 (without DAC)
Ipamorelin
Research suggests Ipamorelin and CJC-1295 may produce enhanced growth hormone release effects when combined. CJC-1295 provides sustained GHRH receptor stimulation while Ipamorelin provides pulsatile ghrelin receptor stimulation — complementary pathways studied in GH secretion research.
GLP-1 agonists
Research notes metabolic pathway overlap between growth hormone-releasing peptides and GLP-1 agonists. Both compound classes influence metabolic signaling; limited research has studied their combined effects. Consult your prescriber before combining.
CJC-1295 (without DAC)
IGF-1
Where to source these peptides
CJC-1295 (without DAC)
454 listed
Browse directory →
Providers offeringIGF-1
21 listed
Browse directory →
PeptideBase lists providers for educational research purposes only. Always consult a qualified healthcare professional before obtaining or using any peptide.
More GH / IGF Axis Comparisons
Browse all peptides →Educational research tools — not medical advice.
Cite this page
Data last updated August 26, 2026
Free to reference and republish with attribution to PeptideBase. Choose a format:
PeptideBase. (2026). CJC-1295 (without DAC) vs IGF-1 — Per-mg Price Comparison. Retrieved September 12, 2026, from https://peptidebase.io/peptides/compare/cjc-1295/igf-1